Welcome to our dedicated page for Abeona Therapeut SEC filings (Ticker: ABEO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Abeona Therapeutics Inc. (ABEO) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Abeona is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, and its filings offer detailed insight into the business, including the commercialization of ZEVASKYN® (prademagene zamikeracel) for recessive dystrophic epidermolysis bullosa (RDEB) and the development of AAV-based gene therapies for ophthalmic conditions.
Investors can review current reports on Form 8-K, where Abeona reports material events such as quarterly financial results, operational updates on ZEVASKYN manufacturing and launch activities, and transactions like the sale of a Rare Pediatric Disease Priority Review Voucher awarded upon FDA approval of ZEVASKYN. These filings also confirm that Abeona’s common stock, with a par value of $0.01 per share, trades on The Nasdaq Capital Market under the symbol ABEO.
In addition to 8-Ks, users can access annual reports on Form 10-K and quarterly reports on Form 10-Q (when available) for information on Abeona’s research and development spending, selling, general and administrative expenses related to the ZEVASKYN launch, cash and investment balances, debt obligations, and risk factor disclosures relevant to its gene therapy programs and manufacturing operations.
Stock Titan enhances these documents with AI-powered summaries that help explain key sections of lengthy filings, such as revenue descriptions, cost structures, and updates on regulatory interactions. The platform also surfaces insider transaction reports on Form 4 when filed, enabling users to track equity awards and other changes in beneficial ownership by Abeona’s officers and directors.
By combining real-time EDGAR updates with AI-generated highlights, this ABEO filings page is designed to make Abeona’s complex biopharmaceutical and gene therapy disclosures more accessible to investors, analysts, and other interested readers.
Abeona Therapeutics investor plans small stock sale under Rule 144. A notice was filed to potentially sell 18,666 shares of Abeona Therapeutics common stock through broker Stifel Nicolaus & Company on or after 01/22/2026 on the Nasdaq market. The aggregate market value of the proposed sale is listed as $99,507.00.
The shares relate to equity compensation. The filer acquired 48,169 shares of common stock on 01/21/2026 through restricted stock units granted by the issuer, with “equity compensation” described as the form of payment. The filing also notes that 51,191,361 shares of Abeona common stock were outstanding, providing context for the size of the planned sale.
ABEO has a planned insider sale under Rule 144. A holder has filed to sell 13,578 shares of common stock through broker Stifel Nicolaus & Company Inc., with an aggregate market value of $73,233.00. The shares relate to an award of 38,535 restricted stock units the holder acquired from the issuer on 01/21/2026 as equity compensation, with the planned sale date around 01/22/2026 on the Nasdaq exchange.
The filing notes that 54,191,361 shares of common stock were outstanding, providing context for the size of the planned sale relative to the company’s total share count.
Abeona Therapeutics (ABEO) insider Vishwas Seshadri has filed a notice of proposed stock sales under Rule 144. The filing covers 69,832 shares of common stock to be sold through Stifel Nicolaus & Company on the Nasdaq exchange, with an aggregate market value of
The securities to be sold were acquired on
Abeona Therapeutics Inc. director Mark Alvino reported selling 13,500 shares of the company’s common stock on 01/21/2026. The shares were sold at a weighted average price of $5.2277 per share, with individual trade prices ranging from $5.21 to $5.235. After this transaction, he beneficially owns 48,752 common shares directly.
The filing notes that detailed price and size information for each individual trade within the reported price range is available upon request from the company, any security holder, or the SEC staff.
A stockholder has filed a notice of intent to sell 13,500 shares of common stock, with an aggregate market value of $70,574, through broker Stifel Nicolaus & Company Inc. on or around 01/21/2026 on the Nasdaq exchange. These shares were acquired from the issuer on 07/08/2025 as restricted stock units granted as equity compensation, and became payable in shares on the same date.
Over the past three months, the person for whose account the securities are to be sold has already sold 15,000 shares of common stock, generating $71,168 in gross proceeds. By signing the notice, the seller represents that they are not aware of any material adverse, nonpublic information about the issuer’s current or prospective operations.
Abeona Therapeutics reported an insider equity award to its Chief Financial Officer, Joseph Walter Vazzano. On January 20, 2026, he received 133,595 shares of common stock as restricted stock at a price of $0.00 per share, indicating a stock-based compensation grant rather than an open-market purchase. According to the disclosure, these restricted shares will vest in three equal installments on January 20, 2027, January 20, 2028, and January 20, 2029. Following this grant, Vazzano directly beneficially owns 587,226 shares of Abeona Therapeutics common stock.
Abeona Therapeutics Inc. disclosed an equity grant to its Chief Executive Officer and director, Vishwas Seshadri. On January 20, 2026, he received 365,422 shares of common stock as restricted stock at a price of $0.00 per share. After this award, he beneficially owned 1,530,240 shares of Abeona common stock in total.
The restricted stock will vest in three equal installments, with one-third of the shares scheduled to vest on each of January 20, 2027, January 20, 2028, and January 20, 2029, aligning the CEO’s compensation with the company’s multi‑year performance.
Abeona Therapeutics reported an insider equity award for its SVP and Chief Legal Officer, Brendan M. O'Malley. On January 20, 2026, he received 113,949 shares of common stock as restricted stock at a price of $0.00 per share, reflecting a compensatory grant rather than an open-market purchase.
The restricted stock will vest in three equal installments, with one-third vesting on January 20, 2027, one-third on January 20, 2028, and the final third on January 20, 2029. Following this award, O'Malley beneficially owns 464,712 shares of Abeona Therapeutics common stock, held directly.
Abeona Therapeutics (ABEO) reported Q3 2025 results, reflecting the first months after FDA approval of ZEVASKYN for RDEB. The quarter showed a net loss of $5.2 million$30.3 million loss a year ago, as commercialization spending ramped. Year-to-date, the company recorded $91.6 million in net income, largely from a $152.4 million gain on the sale of a Priority Review Voucher.
Liquidity strengthened: cash and cash equivalents were $82.9 million and short‑term investments were $124.2 million as of September 30, 2025. Stockholders’ equity rose to $171.2 million. Q3 operating expenses included R&D $4.2 million and SG&A $19.3 million as the company built out commercial infrastructure and manufacturing capacity. Inventory totaled $4.9 million (raw materials). Warrant liabilities declined to $22.6 million. The company maintained a $20.0 million senior term loan; an amendment on July 18, 2025 reduced the interest rate to a fixed 11.75% and included issuance of 16,473 new warrants. Common shares outstanding were 54,191,361 as of November 7, 2025.
Abeona Therapeutics Inc. (ABEO) furnished quarterly results information. The company reported that it issued a press release regarding its financial results for the quarter ended September 30, 2025, and furnished it under Item 2.02.
The full text of the release is included as Exhibit 99.1. As stated, the information under Item 2.02 and Exhibit 99.1 is furnished and not deemed “filed” for purposes of Section 18 of the Exchange Act, and is not incorporated by reference except as expressly set forth by specific reference.